Zhang, Qingyuan
Shao, Bin
Tong, Zhongsheng
Ouyang, Quchang
Wang, Yuting
Xu, Guoying
Li, Shaorong
Li, Huiping
Funding for this research was provided by:
Jiangsu Hengrui Medicine
Article History
Received: 31 May 2022
Accepted: 12 August 2022
First Online: 3 October 2022
Declarations
:
: The trial was done in accordance with the Declaration of Helsinki and the International Council for Harmonization Good Clinical Practice. The study protocol was approved by the independent ethics committee of Harbin Medical University Cancer Hospital (2019–163), Peking University Cancer Hospital and Institute (2019YW55-ZY02), Tianjin Medical University Cancer Institute and Hospital (E2020029), and Hunan Cancer Hospital (2019–304). All patients provided written informed consent before enrolment.
: Not applicable.
: YW, GX, and SL are employees of Jiangsu Hengrui Pharmaceuticals. Other authors have no potential conflict of interest to declare.